Possible 特例承認 against MSD株式会社
For developers: integration details
You do not need this for normal browsing. Use it when integrating this enforcement record into an internal tool or AI workflow.
/api/v1/enforcements?company=MSD%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE&limit=10Action summary
- Company
- MSD株式会社Japanese originalOriginal: MSD株式会社
- Entity match
- Possible entity match60/100Machine extractedCompany name extracted from the Japanese public disclosure
- Governing law
- 医薬品医療機器等法医薬品医療機器等法
- Action type
- 特例承認特例承認
- Action date
- 24 December 2021
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Name of the COVID-19 treatment drug: Lagebrio Capsules 200mg, Generic name: Molnupiravir, Applicant: MSD Corporation, Application date: December 3, 2021 (Reiwa 3).
Show original Japanese text
新型コロナウイルス感染症に係る治療薬の販売名：ラゲブリオカプセル200mg、一般名：モルヌピラビル、申請者：MSD株式会社、申請日：令和３年12月３日
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under 医薬品医療機器等法.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-25T00:20:15.406+00:00
- Evidence checked
- 2026-04-25T00:20:15.406+00:00
- Archive captured
- 2026-04-09T18:02:19.818+00:00
Show audit JSON
{
"record": {
"id": "01dd8e57-c35b-458f-878a-78148a1d3dd8",
"url": "https://regbase.jp/en/enforcement/other-msd-20211224",
"company_name_original": "MSD株式会社",
"company_name_registry": "MSD株式会社",
"corporate_number": null,
"law": {
"ja": "医薬品医療機器等法",
"en": "医薬品医療機器等法"
},
"action_type": {
"ja": "特例承認",
"en": "特例承認"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "possible",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": null
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Japanese regulatory disclosure under 医薬品医療機器等法."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/other-msd-20211224",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/newpage_23047.html",
"archiveUrl": "https://kiroku.today/view/d15e5529b3rsb549",
"archiveCapturedAt": "2026-04-09T18:02:19.818+00:00",
"extractedAt": "2026-04-25T00:20:15.406+00:00",
"translatedAt": "2026-05-01T07:08:38.739+00:00",
"evidenceCheckedAt": "2026-04-25T00:20:15.406+00:00",
"generatedAt": "2026-06-19T11:42:09.688Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.